Celgene wins key FDA ok ahead of BMS merger

The U.S. FDA has approved Celgene ' s rare bone marrow cancer drug, Inrebic, giving the drugmaker a big regulatory win ahead of its proposed merger with Bristol-Myers Squibb.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news